Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Eiji Kirino. (2012) Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Preference and Adherence 6, pages 853-861.
Read now
Read now
Rodrigo CL Edelmuth, Michael A Nitsche, Linamara Battistella & Felipe Fregni. (2010) Why do some promising brain-stimulation devices fail the next steps of clinical development?. Expert Review of Medical Devices 7:1, pages 67-97.
Read now
Read now
Sidney H. Kennedy, Henning F. Andersen & Michael E. Thase. (2009) Escitalopram in the treatment of major depressive disorder: A meta-analysis. Current Medical Research and Opinion 25:1, pages 161-175.
Read now
Read now
Feng Xie, Nicolas Despiegel, Natalya Danchenko & Karina Hansen. (2009) Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice 13:1, pages 59-69.
Read now
Read now
Eleanor L Olvey & Grant H Skrepnek. (2008) The cost-effectiveness of sertraline in the treatment of depression. Expert Opinion on Pharmacotherapy 9:14, pages 2497-2508.
Read now
Read now
Cyril Höschl & Jaromír Švestka. (2008) Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics 8:4, pages 537-552.
Read now
Read now
Edward P. Armstrong, Daniel C. Malone & M. Haim Erder. (2008) A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder. Current Medical Research and Opinion 24:4, pages 1115-1121.
Read now
Read now
Raymond W Lam & Lieven Annemans. (2007) Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, pages 559-576.
Read now
Read now
Edward P. Armstrong, Grant H. Skrepnek & M. Haim Erder. (2007) Cost–utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Current Medical Research and Opinion 23:2, pages 251-258.
Read now
Read now
Articles from other publishers (26)
Juntao Yin, Xiaoyong Song, Chaoyang Wang, Xuhong Lin & Mingsan Miao. (2023) Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis. BMC Psychiatry 23:1.
Crossref
Crossref
Vishal Bhatia, Ashwani K. Dhingra, Bhawna Chopra & Kumar Guarve. (2023) A Review of Clinical Studies Assessing the Therapeutic Efficacy of
Escitalopram: A Step Towards Development. CNS & Neurological Disorders - Drug Targets 22:1, pages 41-50.
Crossref
Crossref
Calvin Diep, Norma Rosenek, Yuelee Khoo, Wiebke Gandhi, Carien M. van Reekum, Arun V. Ravindran, Karim S. Ladha, Benicio N. Frey, Roumen V. Milev, Susan Rotzinger, Raymond W. Lam, Sidney H. Kennedy, Wendy Lou, Tim Salomons & Venkat Bhat. (2022) Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report. Psychiatry Research 312, pages 114557.
Crossref
Crossref
Lorenzo Guizzaro, David Dickinson Vaughan Morgan, Andrea Falco & Ciro Gallo. (2020) Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial level. Journal of Clinical Epidemiology 124, pages 106-117.
Crossref
Crossref
Nathalia Zak, Erlend Bøen, Birgitte Boye, Ole A. Andreassen, Nhat Trung Doan, Ulrik F. Malt, Lars T. Westlye & Torbjørn Elvsåshagen. (2019) Mood episodes are associated with increased cortical thinning: A longitudinal study of bipolar disorder type II. Bipolar Disorders 21:6, pages 525-538.
Crossref
Crossref
W. Bentley MacLeod. (2017) Viewpoint: The human capital approach to inference. Canadian Journal of Economics/Revue canadienne d'économique 50:1, pages 5-39.
Crossref
Crossref
David F. Lehmann & Sarabeth Wojnowicz. (2015) The Evergreening of Biopharmaceuticals: Time to Defoliate. The Journal of Clinical Pharmacology 56:4, pages 383-389.
Crossref
Crossref
Eiji Kirino. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
465
476
.
Ai Leng Khoo, Hui Jun Zhou, Monica Teng, Liang Lin, Ying Jiao Zhao, Lay Beng Soh, Yee Ming Mok, Boon Peng Lim & Kok Peng Gwee. (2015) Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants. CNS Drugs 29:8, pages 695-712.
Crossref
Crossref
Barbara Nussbaumer, Laura C. Morgan, Ursula Reichenpfader, Amy Greenblatt, Richard A. Hansen, Megan Van Noord, Linda Lux, Bradley N. Gaynes & Gerald Gartlehner. (2014) Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis. CNS Drugs 28:8, pages 699-712.
Crossref
Crossref
Ursula Reichenpfader, Gerald Gartlehner, Laura C. Morgan, Amy Greenblatt, Barbara Nussbaumer, Richard A. Hansen, Megan Van Noord, Linda Lux & Bradley N. Gaynes. (2013) Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis. Drug Safety 37:1, pages 19-31.
Crossref
Crossref
Christina F Bisgaard, Steffen Bak, Trine Christensen, Ole N Jensen, Jan J Enghild & Ove Wiborg. (2012) Vesicular signalling and immune modulation as hedonic fingerprints: proteomic profiling in the chronic mild stress depression model. Journal of Psychopharmacology 26:12, pages 1569-1583.
Crossref
Crossref
Gerald Gartlehner, Kylie Thaler, Seth Hill & Richard A. Hansen. (2012) How Should Primary Care Doctors Select Which Antidepressants to Administer?. Current Psychiatry Reports 14:4, pages 360-369.
Crossref
Crossref
Hossein Haji Ali Afzali, Jonathan Karnon & Jodi Gray. (2012) A Critical Review of Model-Based Economic Studies of Depression. PharmacoEconomics 30:6, pages 461-482.
Crossref
Crossref
Hye Yoon Park, Byoung-Jo Lee, Jong-Hoon Kim, Jae-Nam Bae & Bong-Jin Hahm. (2012) Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: A 12-week, open-label prospective trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry 36:2, pages 318-323.
Crossref
Crossref
T. Christensen, C.F. Bisgaard & O. Wiborg. (2011) Biomarkers of anhedonic-like behavior, antidepressant drug refraction, and stress resilience in a rat model of depression. Neuroscience 196, pages 66-79.
Crossref
Crossref
Dan J. Stein & Ana Garcia Lopez. (2011) Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. Advances in Therapy 28:11, pages 1021-1037.
Crossref
Crossref
George I. Papakostas & Klaus Larsen. (2010) Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. European Archives of Psychiatry and Clinical Neuroscience 261:3, pages 147-156.
Crossref
Crossref
Karly P. Garnock-Jones & Paul L. McCormack. (2010) Escitalopram. CNS Drugs 24:9, pages 769-796.
Crossref
Crossref
Brian Leonard & David Taylor. (2010) Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression. Journal of Psychopharmacology 24:8, pages 1143-1152.
Crossref
Crossref
Andrea Cipriani, Teresa La Ferla, Toshi A Furukawa, Alessandra Signoretti, Atsuo Nakagawa, Rachel Churchill, Hugh McGuire & Corrado Barbui. (2010) Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Andrea Cipriani, Claudio Santilli, Toshi A Furukawa, Alessandra Signoretti, Atsuo Nakagawa, Hugh McGuire, Rachel Churchill & Corrado Barbui. (2009) Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2016:5.
Crossref
Crossref
Andrea Cipriani, Teresa La Ferla, Toshi A Furukawa, Alessandra Signoretti, Atsuo Nakagawa, Rachel Churchill, Hugh McGuire & Corrado Barbui. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Andrea Cipriani, Toshiaki A Furukawa, Georgia Salanti, John R Geddes, Julian PT Higgins, Rachel Churchill, Norio Watanabe, Atsuo Nakagawa, Ichiro M Omori, Hugh McGuire, Michele Tansella & Corrado Barbui. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet 373:9665, pages 746-758.
Crossref
Crossref
Gerald Gartlehner, Patricia Thieda, Richard A Hansen, Bradley N Gaynes, Angela DeVeaugh-Geiss, Erin E Krebs & Kathleen N Lohr. (2008) Comparative Risk for Harms of Second-Generation Antidepressants. Drug Safety 31:10, pages 851-865.
Crossref
Crossref
David S Baldwin, Elin Heldbo Reines, Christina Guiton & Emmanuelle Weiller. (2016) Escitalopram Therapy for Major Depression and Anxiety Disorders. Annals of Pharmacotherapy 41:10, pages 1583-1592.
Crossref
Crossref